Emergent Biosolutions
EBS
340 hedge funds and large institutions have $4.13B invested in Emergent Biosolutions in 2021 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 126 increasing their positions, 138 reducing their positions, and 50 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% more capital invested
Capital invested by funds: $3.96B → $4.13B (+$167M)
0.2% more ownership
Funds ownership: 83.54% → 83.74% (+0.2%)
0% less call options, than puts
Call options by funds: $12.8M | Put options by funds: $12.8M
9% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 138
4% less funds holding
Funds holding: 353 → 340 (-13)
16% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$186M |
| 2 |
BlackRock
New York
|
+$34M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$22.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$18.9M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$43.2M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$24.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.8M |
| 4 |
Jennison Associates
New York
|
-$23.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.3M |
EBS Hedge Fund Activity: Q1 2021 in Review
340 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2021, worth a combined $4.13B — up 4.2% from $3.96B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of EBS and 42 opened new positions — a net loss of 8 holders — while 138 trimmed existing stakes and 126 added.
The largest buyer was Janus Henderson Group, adding an estimated $186M. The largest seller was Goldman Sachs, cutting an estimated $43.2M.
- 340 institutional investors held Emergent Biosolutions (EBS) as of Q1 2021, down from 353 in Q4 2020.
- Funds reported $4.13B of Emergent Biosolutions stock for Q1 2021, up 4.2% quarter-over-quarter.
- 42 funds opened new Emergent Biosolutions positions in Q1 2021 and 50 closed out, a net change of -8 holders.
- The largest Emergent Biosolutions buyer in Q1 2021 was Janus Henderson Group, an estimated $186M added.
- The largest Emergent Biosolutions seller in Q1 2021 was Goldman Sachs, an estimated $43.2M sold.
Based on aggregated 13F filings for Q1 2021.